Double Blind Positive Control – 2.5% PAAG Hydrogel

Reasons for performing the study:

Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking equestrian disciplines. To date there have been no studies evaluating its’ efficacy in inter-carpal (knee) joints of racehorses conducted at an acceptable standard. (continue)

 

Objectives:

To investigate the efficacy of a 2.5% PAAG (Arthramid Vet) in the management of inter-carpal joint lameness in racing Thoroughbreds.

Study design: 

Prospective double-blinded positive-control study. 

Methods:

33 flat-racing Thoroughbreds in full training at a single training facility with lameness (AAEP 1-3/5) localised to the inter-carpal joint by intra-articular analgesia and radiological assessment were enrolled. Horses were randomly allocated to be treated intra-articularly with either 2ml of a 2.5% polyacrylamide hydrogel, 12mg of triamcinolone acetonide or 20mg of sodium hyaluron (followed by 2 further intravenous treatments of 40mg, at weekly intervals), by the treating veterinarian. All horses were rested for 48 hours’ post-treatment and then re-entered an unaltered training regime.

Subsequent examinations at 2, 4, and 6 weeks were performed by the blinded examining veterinarian for all groups. Horses treated with the 2.5% PAAG (Arthramid Vet) were monitored through to 12 weeks for reoccurrence of lameness in the treated joint.

Results:

Compared to horses that received triamcinolone acetonide or sodium hyaluron, horses treated with 2.5% PAAG (Arthramid Vet) showed a greater chance of resolution of lameness, joint effusion and reaction to passive flexion at four (p<0.05) and six (p<0.05) weeks, with no difference seen between groups at 2 weeks. There was no significant difference between the triamcinolone acetonide and sodium hyaluronate groups at any time point. Two-thirds of horses treated with the 2.5% PAAG hydrogel were still lame-free at 12 weeks. 

Conclusions:

This study indicates that a 2.5% PAAG (Arthramid Vet) hydrogel can be used in the management of inter-carpal joint lameness in flat-racing Thoroughbreds and was superior to and longer lasting than both Triamcinalone and Hyaluronic Acid. A reduction in joint effusion and reaction to passive flexion aligns with the proposed mode of action of Arthramid Vet.

Table 1: Pre-admission variables per treatment group. There was no statistically significant different between treatment groups.
 

PAAG

TA

HA

Number

12

11

10

Age: range (mean)

2-5 (3.08)

2-4 (3)

2-6 (2.8)

Sprinter (%)

5 (42)

5 (45)

4 (40)

Miler (%)

5 (42)

4 (36)

4 (40)

Stayer (%)

2 (16)

2 (19)

2 (20)

Lameness range (mean)

1-3 (1.67)

1-4 (2.18)

1-3 (1.8)

Effusion range (mean)

0-2 (0.5)

0-1 (0.1)

0-2 (0.2)

Reaction to flexion range (mean)

0-2 (0.67)

 0-2 (0.54)

0-2(0.6)

Radiological score range (mean)

0-2 (0.5)

0-2 (0.63)

0-2 (0.6)

Lameness Outcome By Treatment At 6 Weeks
Joint Effusion Outcome By Treatment At 6 Weeks
Reaction To passive Flexion Outcome By Treatment At 6 Weeks

Our Manufacturing Policy

Every detail is taken care of

We realised early on that quality assurance is everything when you need a product that an animal’s health and well-being relies on. We needed to know every step of the manufacturing process; to ensure the quality and integrity of our products. All materials are stored at a constant temperature and humidity to ensure consistency within manufacturers recommendations. We want to make sure every detail is taken care of in the best way possible and we only work with suppliers that hold the same values.

JOINT LAMENESS & OSTEOARTHRITIS

Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses.

CLINICAL SAFETY IN APPLICATION

Both in vitro and in vivo studies have taken place, of Arthramid Vet to support regulatory submissions for market authorisation.

Industry Changing Innovations

Integrity in every product

For professional athletes, both human and equine alike, banned substance testing carries fear for even those riders and trainers making every effort to stay compliant. We want to ensure the integrity of every product we recommend meets local racing and regulatory authority requirements with the finished product being extensively tested for quality, potency and banned substances.

Get In Touch

I am Interested In

Order Request

32 Hill Road, Cambridge, NZ
Phone +64 (09) 8013 253
E: sales@imsvet.com

Innovative Medical Solutions

Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz  for registration conditions.

32 Hill Road, Cambridge
PO Box 1083, Cambridge 3450
Phone +64 (09) 8013 253
sales@imsvet.com